Clinical Trial

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 10, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-23; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2025-06-28
Trial Details
NCT Number NCT07001150
Lead Sponsor Tanta University
Collaborators: Prof. Sahar Kamal Hegazy,Head of Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University, Dr. Raed Ahmed Abdel-Maboud,Lecturer of neurology,Faculty of Medicine,Tanta University
Conditions Parkinson Disease
Enrollment 50 participants
Start Date 2025-05-10
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-10